CT-152 significantly outperformed sham control as an adjunct to ADT monotherapy in improving CGI-S and PHQ-9 scores among adults with MDD.

Early initiation of pimavanserin among patients with Parkinson disease psychosis were more likely to experience complete symptom resolution.

Over 30% of adults with ADHD treated with viloxazine ER experienced a 5% or greater sustained decrease in their baseline body weight.

Esketamine for TRD demonstrated efficacy in reducing depressive symptoms and did not significantly differ based on TMS treatment history.

Anhedonia in MDD was associated with high psychotropic medication use, health care utilization, and polypharmacy, as well as poor HRQoL.

Relative to placebo, lumateperone significantly improved MADRS, CGI-S, and QIDS-SR-16 scores by day 43 among patients with MDD.

AXS-05 was associated with a significant and rapid reduction in AD agitation and was generally well tolerated across studies.

High-dose centanafadine was well-tolerated and outperformed placebo in improving ADHD symptoms among children and adolescents with ADHD.

Teletherapy can increase access to mental health care for patients experiencing intimate partner violence – when delivered ...

COVID-19 vaccination is associated with a reduced risk for most cardiovascular events, but with slightly increased risks of extrasystoles and transient ischemic attack, as well as myocarditis and ...

Pain interference had little effect on alcohol use days per month among AIAN adolescents with high levels of Tribal identity.

Exposure to maternal COVID-19 is not associated with abnormal neurodevelopmental screening results through 24 months postpartum.